Golden State Equity Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Golden State Equity Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$368K	Buy	476 +121	+34%	+$92.6K	0.03%	528
2025 Q4	$274K	Sell	355 -591	-62%	-$401K	0.04%	417
2025 Q3	$532K	Buy	946 +71	+8%	+$40.1K	0.09%	247
2025 Q2	$459K	Sell	875 -571	-39%	-$319K	0.09%	260
2025 Q1	$917K	Buy	1,446 +88	+6%	+$60.5K	0.18%	141
2024 Q4	$967K	Buy	1,358 +1,272	+1,479%	+$1.07M	0.18%	134
2024 Q3	$90.4K	Buy	+86	New	+$95.7K	0.05%	292
2021 Q3	–	Sell	-558	Closed	-$312K	–	273
2021 Q2	$312K	Buy	+558	New	+$283K	0.12%	172

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Golden State Equity Partners's REGN Position: Q1 2026 in Review

Golden State Equity Partners increased its Regeneron Pharmaceuticals (REGN) stake by 34% in Q1 2026, buying an estimated $92.6K and bringing the position to 476 shares worth $368K. The position accounts for 0.03% of the portfolio, ranked #528.

Golden State Equity Partners first reported a position in REGN in Q2 2021 and has held it in 8 quarters since. The position peaked at $967K in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Golden State Equity Partners held 476 shares of Regeneron Pharmaceuticals worth $368K as of Q1 2026.
Golden State Equity Partners bought 121 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $92.6K.
Regeneron Pharmaceuticals made up 0.03% of Golden State Equity Partners's portfolio in Q1 2026, its #528 holding.
Golden State Equity Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
Golden State Equity Partners's Regeneron Pharmaceuticals position peaked at $967K in Q4 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.